Log in
Enquire now
‌

US Patent 8026247 Bicyclic amides as kinase inhibitors

Patent 8026247 was granted and assigned to Novartis on September, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Novartis
Novartis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
80262470
Patent Inventor Names
Andreas Floersheimer0
Andrea Vaupel0
Giorgio Caravatti0
Guido Bold0
Hans-Georg Capraro0
Pascal Furet0
Paul W. Manley0
Date of Patent
September 27, 2011
0
Patent Application Number
115750250
Date Filed
September 14, 2005
0
Patent Citations Received
‌
US Patent 11851434 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
0
‌
US Patent 11998545 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
0
‌
US Patent 11964988 Fused heterocyclic compounds as RET kinase inhibitors
0
Patent Primary Examiner
‌
Kahsay T. Habte
0
Patent abstract

The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8026247 Bicyclic amides as kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.